Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]
Werewolf Therapeutics, Inc. (HOWL)
Company Research
Source: Yahoo! Finance
On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and next-generation INDUCER T cell engager platform. Management said they observed strong monotherapy and combination activity with WTX-124 in heavily pretreated melanoma, cutaneous squamous cell carcinoma, and gastroesophageal junction cancer, with objective response rates of 21-30% in select populations. Tumor regression in roughly 33% of lesions was reported, alongside a favorable tolerability profile, including no vascular leak syndrome and manageable grade 3-4 adverse events (27/106 and 2/106). Moreover, the FDA accepted 18mg as the recommended dose, providing guidance for a monotherapy registration path in relapsed/refractory melanoma. At the same time, WTX-330 continues to demonstrate strong momentum, showing promising antitumor activity in difficult-to-treat cancers, along with an optim
Show less
Read more
Impact Snapshot
Event Time:
HOWL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOWL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOWL alerts
High impacting Werewolf Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOWL
News
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Werewolf Therapeutics Announces Pipeline and Business UpdatesGlobeNewswire
HOWL
Earnings
- 11/4/25 - Beat
HOWL
Sec Filings
- 1/16/26 - Form SCHEDULE
- 1/15/26 - Form 4
- 1/12/26 - Form 4
- HOWL's page on the SEC website